 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes THIOTHIXENE increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does the FDA label for THIOTHIXENE mention an increased or decreased risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes the FDA label for THIOTHIXENE mention an increased or decreased risk of[0m
[32mbleeding?[0m
 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes the FDA label for THIOTHIXENE mention an increased or decreased risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does THIOTHIXENE mention an increased or decreased risk of bleeding in its FDA label?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"THIOTHIXENE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: THIOTHIXENE: boxed_warning: WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs [0m
[31mare at an increased risk of death. Analyses of seventeen placebo-controlled trials [0m[1;31m([0m[31mmodal duration of [0m[1;31m10[0m[31m weeks[0m[1;31m)[0m[31m, largely in patients taking atypical antipsychotic drugs, revealed a risk of death in [0m
[31mdrug-treated patients of between [0m[1;31m1.6[0m[31m to [0m[1;31m1.7[0m[31m times the risk of death in placebo-treated patients. Over the course of a typical [0m[1;31m10[0m[31m-week controlled trial, the rate of death in drug-treated patients was [0m
[31mabout [0m[1;31m4.5[0m[31m%, compared to a rate of about [0m[1;31m2.6[0m[31m% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular [0m[1;31m([0m[31me.g., heart failure, sudden death[0m[1;31m)[0m
[31mor infectious [0m[1;31m([0m[31me.g., pneumonia[0m[1;31m)[0m[31m in nature. THIOTHIXENE: boxed_warning: Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may [0m
[31mincrease mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some [0m[1;31mcharacteristic[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m of the patients is[0m
[31mnot clear. Thiothixene is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: precautions: Leukopenia, Neutropenia and Agranulocytosis Class Effect In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia and agranulocytosis have[0m
[31mbeen reported temporally related to antipsychotic agents. Possible risk factors for leukopenia/neutropenia include preexisting low white blood cell count [0m[1;31m([0m[31mWBC[0m[1;31m)[0m[31m and history of drug induced [0m
[31mleukopenia/neutropenia. Patients with a history of a clinically significant low WBC or drug induced leukopenia/neutropenia should have their complete blood count [0m[1;31m([0m[31mCBC[0m[1;31m)[0m[31m monitored frequently during the [0m
[31mfirst few months of therapy and discontinuation of thiothixene should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. Patients [0m
[31mwith clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. THIOTHIXENE: precautions: [0m
[31mPatients with severe neutropenia [0m[1;31m([0m[31mabsolute neutrophil count < [0m[1;31m1000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m should discontinue thiothixene and have their WBC followed until recovery. Information for Patients Given the likelihood that [0m
[31msome patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about [0m
[31mthis risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided. [0m
[31mDrug Interactions Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. Patients receiving these drugs should be observed[0m
[31mfor signs of reduced thiothixene effectiveness [0m[1;31m4[0m[31m,[0m[1;31m5[0m[31m . THIOTHIXENE: precautions: Due to a possible additive effect with hypotensive agents, patients receiving these drugs should be observed closely for [0m
[31msigns of excessive hypotension when thiothixene is added to their drug regimen [0m[1;31m6[0m[31m .         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: warnings: WARNINGS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are [0m
[31mat an increased risk of death. Thiothixene is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee BOXED WARNING [0m[1;31m)[0m[31m. Tardive Dyskinesia Tardive dyskinesia, a syndrome [0m
[31mconsisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs, including thiothixene [0m[1;31m1[0m[31m . Although the prevalence of the syndrome [0m
[31mappears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely[0m
[31mto develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. THIOTHIXENE: warnings: Both the risk of developing the syndrome and the [0m
[31mlikelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, [0m
[31mthe syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established cases of tardive dyskinesia, although the [0m
[31msyndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress [0m[1;31m([0m[31mor partially suppress[0m[1;31m)[0m[31m the signs and symptoms of the [0m
[31msyndrome and thereby may possibly mask the underlying disease process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, [0m
[31mantipsychotics should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. THIOTHIXENE: warnings: Chronic antipsychotic treatment should generally be [0m
[31mreserved for patients who suffer from a chronic illness that, [0m[1;31m1[0m[1;31m)[0m[31m is known to respond to antipsychotic drugs, and [0m[1;31m2[0m[1;31m)[0m[31m for whom alternative, equally effective, but potentially less harmful treatments are[0m
[31mnot available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The [0m
[31mneed for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. However, [0m
[31msome patients may require treatment despite the presence of the syndrome. [0m[1;31m([0m[31mFor further information about the description of tardive dyskinesia and its clinical detection, please refer to â€œ Information[0m
[31mfor Patients â€ in the PRECAUTIONS section, and to the ADVERSE REACTIONS section.         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: adverse_reactions: Persistent Tardive Dyskinesia As with all antipsychotic agents, tardive dyskinesia may appear in some patients on long-term therapy with thiothixene [0m[1;31m1[0m[31m or may [0m
[31moccur after drug therapy has been discontinued. The syndrome is characterized by rhythmical involuntary movements of the tongue, face, mouth or jaw [0m[1;31m([0m[31me.g., protrusion of tongue, puffing of cheeks, [0m
[31mpuckering of mouth, chewing movements[0m[1;31m)[0m[31m. Sometimes these may be accompanied by involuntary movements of extremities. Since early detection of tardive dyskinesia is important, patients should be [0m
[31mmonitored on an ongoing basis. It has been reported that fine vermicular movement of the tongue may be an early sign of the syndrome. If this or any other presentation of the syndrome is observed, the[0m
[31mclinician should consider possible discontinuation of antipsychotic medication [0m[1;31m([0m[31msee WARNINGS section[0m[1;31m)[0m[31m. THIOTHIXENE: adverse_reactions: Hepatic Effects Elevations of serum transaminase and alkaline [0m
[31mphosphatase, usually transient, have been infrequently observed in some patients. No clinically confirmed cases of jaundice attributable to thiothixene have been reported. Hematologic Effects As is [0m
[31mtrue with certain other psychotropic drugs, leukopenia and leukocytosis, which are usually transient, can occur occasionally with thiothixene. Other antipsychotic drugs have been associated with [0m
[31magranulocytosis, eosinophilia, hemolytic anemia, thrombocytopenia and pancytopenia. Allergic Reactions Rash, pruritus, urticaria, photosensitivity and rare cases of anaphylaxis have been reported with[0m
[31mthiothixene. Undue exposure to sunlight should be avoided. THIOTHIXENE: adverse_reactions: Although not experienced with thiothixene, exfoliative dermatitis and contact dermatitis [0m[1;31m([0m[31min nursing [0m
[31mpersonnel[0m[1;31m)[0m[31m have been reported with certain phenothiazines. Endocrine/Reproductive Hyperprolactinemia [0m[1;31m3[0m[31m , lactation, menstrual irregularities, moderate breast enlargement and amenorrhea have occurred [0m
[31min a small percentage of females receiving thiothixene. If persistent, this may necessitate a reduction in dosage or the discontinuation of therapy. Phenothiazines have been associated with false [0m
[31mpositive pregnancy tests, gynecomastia, hypoglycemia, hyperglycemia and glycosuria. Autonomic Effects Dry mouth, blurred vision, nasal congestion, constipation, increased sweating, increased [0m
[31msalivation and impotence have occurred infrequently with thiothixene therapy. Phenothiazines have been associated with miosis, mydriasis, and adynamic ileus. THIOTHIXENE: adverse_reactions: Other [0m
[31mAdverse Reactions Hyperpyrexia, anorexia, nausea, vomiting, diarrhea, increase in appetite and weight, weakness or fatigue, polydipsia, and peripheral edema. Although not reported with thiothixene, [0m
[31mevidence indicates there is a relationship between phenothiazine therapy and the occurrence of a systemic lupus erythematosus-like syndrome. Neuroleptic Malignant Syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m Please refer to the [0m
[31mtext regarding NMS in the WARNINGS section. NOTE : Sudden deaths have occasionally been reported in patients who have received certain phenothiazine derivatives. In some cases the cause of death was [0m
[31mapparently cardiac arrest or asphyxia due to failure of the cough reflex. In others, the cause could not be determined nor could it be established that death was due to phenothiazine administration. [0m
[31mTHIOTHIXENE: adverse_reactions: To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at [0m[1;31m1[0m[31m-[0m[1;31m877[0m[31m-[0m[1;31m835[0m[31m-[0m[1;31m5472[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch .         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: references: REFERENCES [0m[1;31m1[0m[31m. Worldwide Labeling Safety Report: Dyskinesia and Dyskinesia Tardive and Thiothixene, [0m[1;31m([0m[31m16Apr02[0m[1;31m)[0m[31m. [0m[1;31m2[0m[31m. Worldwide Labeling Safety Report: Neuroleptic [0m
[31mMalignant Syndrome and Thiothixene, [0m[1;31m([0m[31m16Apr02[0m[1;31m)[0m[31m. [0m[1;31m3[0m[31m. Worldwide Labeling Safety Report: Hyperprolactinemia and Thiothixene, [0m[1;31m([0m[31m16Apr02[0m[1;31m)[0m[31m. [0m[1;31m4[0m[31m. Ereshefsky L, Saklad SR, Watanabe MD, et al. Thiothixene [0m
[31mPharmacokinetic Interactions: A Study of Hepatic Enzyme Inducers, Clearance Inhibitors, and Demographic Variables. Journal of Clinical Psychopharmacology, [0m[1;31m11[0m[1;31m([0m[1;31m5[0m[1;31m)[0m[31m:[0m[1;31m296[0m[31mâ€“[0m[1;31m301[0m[31m, [0m[1;31m([0m[1;31m1991[0m[1;31m)[0m[31m. [0m[1;31m5[0m[31m. Worldwide Labeling [0m
[31mSafety Report: Drug Interaction and Thiothixene, [0m[1;31m([0m[31m09May02[0m[1;31m)[0m[31m. [0m[1;31m6[0m[31m. THIOTHIXENE: references: McEvoy GK, Miller JL, Snow EK, et al. AHFS Drug Information. American Society of Health-System Pharmacists, [0m
[31mInc., p. [0m[1;31m2334[0m[31m-[0m[1;31m2336[0m[31m, [0m[1;31m([0m[1;31m2002[0m[1;31m)[0m[31m. [0m[1;31m7[0m[31m. Worldwide Labeling Safety Report: Menstrual Disorder and Thiothixene, [0m[1;31m([0m[31m16Apr02[0m[1;31m)[0m[31m. Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Oral Solid Dosage Unit Ahmedabad [0m
[1;31m382213[0m[31m, INDIA Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ [0m[1;31m08807[0m[31m Rev. THIOTHIXENE: references: [0m[1;31m01[0m[31m-[0m[1;31m2022[0m[31m-[0m[1;31m01[0m[31m         [0m
[31mSOURCE:THIOTHIXENE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The FDA label for THIOTHIXENE does not mention an increased or decreased risk of bleeding. However, it does mention hematologic effects such as leukopenia, leukocytosis, and that other [0m
[32mantipsychotic drugs have been associated with agranulocytosis, eosinophilia, hemolytic anemia, thrombocytopenia, and pancytopenia.[0m

[32mSOURCE: THIOTHIXENE label[0m
[32mEXTRACT_START_END: Hematologic Effects As is true[0m[32m...[0m[32mwith certain phenothiazines.[0m
*[1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The FDA label for THIOTHIXENE does not mention an increased or [0m
[34mdecreased risk of bleeding. However, it does mention hematologic effects such as leukopenia, leukocytosis, and that other antipsychotic drugs have been associated with agranulocytosis, eosinophilia, [0m
[34mhemolytic anemia, thrombocytopenia, and pancytopenia.[0m

[34mSOURCE: THIOTHIXENE label[0m
[34mEXTRACT_START_END: Hematologic Effects As is true[0m[34m...[0m[34mwith certain phenothiazines.[0m
 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if the FDA label for THIOTHIXENE mentions an increased or decreased risk of bleeding."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the FDA label for THIOTHIXENE does not mention an increased or decreased risk of bleeding, but it does mention hematologic effects such as leukopenia, leukocytosis, [0m
[32mand that other antipsychotic drugs have been associated with agranulocytosis, eosinophilia, hemolytic anemia, thrombocytopenia, and pancytopenia."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The FDA label for THIOTHIXENE does not specifically mention an increased or decreased risk of bleeding. However, it does note hematologic effects, which could theoretically affect [0m
[32mbleeding risk, although a direct causal relationship is not established in the label."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does THIOTHIXENE increase or decrease the risk of bleeding?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if the FDA label for THIOTHIXENE mentions an increased or decreased risk of bleeding."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the FDA label for THIOTHIXENE does not mention an increased or decreased risk of bleeding, but it does mention hematologic effects such as leukopenia, leukocytosis, [0m
[34mand that other antipsychotic drugs have been associated with agranulocytosis, eosinophilia, hemolytic anemia, thrombocytopenia, and pancytopenia."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The FDA label for THIOTHIXENE does not specifically mention an increased or decreased risk of bleeding. However, it does note hematologic effects, which could theoretically affect [0m
[34mbleeding risk, although a direct causal relationship is not established in the label."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does THIOTHIXENE increase or decrease the risk of bleeding?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if the FDA label for THIOTHIXENE mentions an increased or decreased risk of bleeding.[0m
[1;31m2[0m[31m. FDAHandler responded that the FDA label for THIOTHIXENE does not mention an increased or decreased risk of bleeding, but it does mention hematologic effects such as leukopenia, leukocytosis, and [0m
[31mthat other antipsychotic drugs have been associated with agranulocytosis, eosinophilia, hemolytic anemia, thrombocytopenia, and pancytopenia.[0m
[31m        -----[0m
[31m        Final answer: The FDA label for THIOTHIXENE does not specifically mention an increased or decreased risk of bleeding. However, it does note hematologic effects, which could theoretically [0m
[31maffect bleeding risk, although a direct causal relationship is not established in the label.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe FDA label for THIOTHIXENE does not specifically mention an increased or decreased risk of bleeding. However, it does note hematologic effects such as leukopenia and leukocytosis, and mentions that[0m
[32mother antipsychotic drugs have been associated with conditions like agranulocytosis, eosinophilia, hemolytic anemia, thrombocytopenia, and pancytopenia, which could theoretically affect bleeding risk.[0m
[32mNonetheless, a direct causal relationship between THIOTHIXENE and bleeding risk is not established in the label.[0m
